<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330288</url>
  </required_header>
  <id_info>
    <org_study_id>19649</org_study_id>
    <nct_id>NCT03330288</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment</brief_title>
  <official_title>Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a TheraflexÂ® Treatment to Evaluate Changes in Pain, Functions in Daily Living, and Quality of Life for an Observation Period up to 64 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how a long-term treatment with Theraflex during&#xD;
      64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily&#xD;
      living, the quality of life and patient satisfaction with treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other information that is planned for evaluation in this study includes consumption of&#xD;
      Theraflex, intake of analgesics for joint pain relief and description of basic patient&#xD;
      characteristics such as age, weight and body mass index and others.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">July 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Pain Intensity Subscale</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Other Symptoms Subscale</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Activity of the Joint Subscale</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Life Quality Subscale</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Compliance With Drug Utilization of Theraflex</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Satisfaction Assessment</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex</measure>
    <time_frame>From enrollment up to 64 weeks</time_frame>
    <description>Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1102</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Participants with Stage I-III Knee osteoarthritis (KOA)</arm_group_label>
    <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Stage I-III Hip osteoarthritis (HOA)</arm_group_label>
    <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theraflex, BAY 874017</intervention_name>
    <description>The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day</description>
    <arm_group_label>Participants with Stage I-III Hip osteoarthritis (HOA)</arm_group_label>
    <arm_group_label>Participants with Stage I-III Knee osteoarthritis (KOA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who will be made aware about the study either by the treating physician OR by a&#xD;
        pharmacist where a patient is purchasing Theraflex&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 45 to 75 years with Hip or Knee OA stage I to III&#xD;
&#xD;
          -  Patient started current treatment with Theraflex not more than 2 weeks prior to&#xD;
             inclusion into the study&#xD;
&#xD;
          -  Personally signed and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients participating in an investigational program with interventions outside of&#xD;
             routine clinical practice&#xD;
&#xD;
          -  Patients with Hip or Knee OA stage 0 or stage IV&#xD;
&#xD;
          -  Patients who have both Hip and Knee OA and OA of any other location&#xD;
&#xD;
          -  Contraindications for use of Theraflex in accordance with approved label(known&#xD;
             hypersensitivity, severe chronic renal failure)&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients who completed a treatment with Theraflex or another combination of Gl+ Ch&#xD;
             less than 5 months before start of the current treatment&#xD;
&#xD;
          -  Patients who completed intra-articular corticosteroids treatment in the last 3 months&#xD;
             to exclusion criteria&#xD;
&#xD;
          -  Patients who completed hyaluronic injections of the lower limbs in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sci-Res Institute of Rheumatology n.a. V.A. Nasonova of RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Many locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 6, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>September 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2021</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03330288/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03330288/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 51 centers in Russian Federation, between 20-Nov-2017 (first participant first visit) and 13-Jul-2020 (Database clean). The Primary Completion date is 18-Mar-2020 (last participant last visit)</recruitment_details>
      <pre_assignment_details>A total of 1111 participants were screened over the course of the study, of which 1102 participants were enrolled in the study. Among them, 824 participants were diagnosed with knee osteoarthritis (KOA), while 278 participants were diagnosed with hip osteoarthritis (HOA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
          <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
        </group>
        <group group_id="P2">
          <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
          <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="824">Enrolled</participants>
                <participants group_id="P2" count="278">Enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="794"/>
                <participants group_id="P2" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switching to a different disease-modifying delayed-release drug SYSADOA</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
          <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
        </group>
        <group group_id="B2">
          <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
          <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="824"/>
            <count group_id="B2" value="278"/>
            <count group_id="B3" value="1102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="6.9"/>
                    <measurement group_id="B2" value="60.3" spread="7.21"/>
                    <measurement group_id="B3" value="60.4" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="728"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="968"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="820"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="1098"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain intensity subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.</description>
          <population>KOA patients and HOA patients are reported separately for each Arm of the study</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.48" spread="16.434"/>
                    <measurement group_id="B2" value="60.97" spread="17.321"/>
                    <measurement group_id="B3" value="NA" spread="NA">Two groups used different scales, so no output for total analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other symptom subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.</description>
          <population>KOA patients and HOA patients are reported separately for each Arm of the study</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.25" spread="18.034"/>
                    <measurement group_id="B2" value="61.17" spread="17.691"/>
                    <measurement group_id="B3" value="NA" spread="NA">Two groups used different scales, so no output for total analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Functional activity of the joint subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.</description>
          <population>KOA patients and HOA patients are reported separately for each Arm of the study</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.46" spread="10.599"/>
                    <measurement group_id="B2" value="65.57" spread="16.515"/>
                    <measurement group_id="B3" value="NA" spread="NA">Two groups used different scales, so no output for total analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Life quality subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.</description>
          <population>KOA patients and HOA patients are reported separately for each Arm of the study</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.99" spread="17.009"/>
                    <measurement group_id="B2" value="46.79" spread="17.507"/>
                    <measurement group_id="B3" value="NA" spread="NA">Two groups used different scales, so no output for total analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient satisfaction assessment</title>
          <description>Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="0.5"/>
                    <measurement group_id="B2" value="3.1" spread="0.42"/>
                    <measurement group_id="B3" value="3.1" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Pain Intensity Subscale</title>
        <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Pain Intensity Subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.</description>
          <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Visit 1(enrollment) to Visit 2 (Week 16-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="798"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.07" spread="16.900"/>
                    <measurement group_id="O2" value="15.59" spread="16.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) toVisit 3 (Week 36-44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.92" spread="17.946"/>
                    <measurement group_id="O2" value="20.06" spread="17.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) toVisit 4 (Week 56-64)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.87" spread="18.815"/>
                    <measurement group_id="O2" value="22.81" spread="19.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Other Symptoms Subscale</title>
        <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Other Symptoms Subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.</description>
          <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Visit 1(enrollment) to Visit 2 (Week 16-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="798"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.48" spread="17.465"/>
                    <measurement group_id="O2" value="12.65" spread="16.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) toVisit 3 (Week 36-44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.87" spread="18.685"/>
                    <measurement group_id="O2" value="17.10" spread="17.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) toVisit 4 (Week 56-64)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.78" spread="19.330"/>
                    <measurement group_id="O2" value="19.93" spread="20.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Functional Activity of the Joint Subscale</title>
        <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Activity of the Joint Subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.</description>
          <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Visit 1(enrollment) to Visit 2 (Week 16-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="798"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.98" spread="11.831"/>
                    <measurement group_id="O2" value="13.26" spread="15.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) to Visit 3 (Week 36-44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.26" spread="13.708"/>
                    <measurement group_id="O2" value="16.41" spread="16.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) to Visit 4 (Week 56-64)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.60" spread="14.503"/>
                    <measurement group_id="O2" value="18.77" spread="18.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Life Quality Subscale</title>
        <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Life Quality Subscale</title>
          <description>KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as [100 - (mean value of all subscale questions * 100) / 4]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.</description>
          <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Visit 1(enrollment) to Visit 2 (Week 16-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="798"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.29" spread="17.888"/>
                    <measurement group_id="O2" value="14.25" spread="18.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) to Visit 3 (Week 36-44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.79" spread="19.625"/>
                    <measurement group_id="O2" value="18.82" spread="18.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) to Visit 4 (Week 56-64)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.87" spread="21.055"/>
                    <measurement group_id="O2" value="22.71" spread="21.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Compliance With Drug Utilization of Theraflex</title>
        <description>Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Compliance With Drug Utilization of Theraflex</title>
          <description>Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.</description>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant followed the recommendations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="753"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant not followed the recommendations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Satisfaction Assessment</title>
        <description>Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Satisfaction Assessment</title>
          <description>Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied</description>
          <population>The outcome measure was analyzed based on participants who has KOOS/HOOS assessment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Visit 1(enrollment) to Visit 2 (Week 16-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="798"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.84"/>
                    <measurement group_id="O2" value="0.8" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) to Visit 3 (Week 36-44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.89"/>
                    <measurement group_id="O2" value="0.9" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Visit 1(enrollment) to Visit 4 (Week 56-64)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.94"/>
                    <measurement group_id="O2" value="0.9" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)</title>
        <description>Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)</title>
          <description>Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.</description>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptomatic therapy with analgesics for the target joint OA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other drug treatment for pain syndrome of the target joint OA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other therapy for the target joint OA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex</title>
        <description>Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.</description>
        <time_frame>From enrollment up to 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
          <group group_id="O2">
            <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
            <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex</title>
          <description>Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.</description>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptomatic therapy with analgesics for the target joint OA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other drug treatment for pain syndrome of the target joint OA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other therapy for the target joint OA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After initial administration of Theraflex up to 64 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Participants With Stage I-III Hip Osteoarthritis (HOA)</title>
          <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
        </group>
        <group group_id="E2">
          <title>Participants With Stage I-III Knee Osteoarthritis (KOA)</title>
          <description>Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="824"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="824"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer</organization>
      <phone>(+) 1-888-8422937</phone>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

